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Background:Mycobacteria down-regulates class II transactivator (CIITA)/MHC-II expression and antigen presentation.
Results: During Mycobacterium bovis BCG infection, iNOS/NO responsive KLF4 induces EZH2 and miR-150 functions to
regulate CIITA expression and thus antigen presentation.
Conclusion: CIITA/MHC-II down-regulation by mycobacteria involves NOTCH/iNOS/NO/KLF4 signaling cross-talk and
functions.
Significance: Identification of novel regulators of host-mycobacteria interactions provides promising therapeutic potential.
Pathogenic mycobacteria employ several immune evasion
strategies such as inhibition of class II transactivator (CIITA)
and MHC-II expression, to survive and persist in host macro-
phages. However, precise roles for specific signaling components
executing down-regulation of CIITA/MHC-II have not been ade-
quately addressed. Here, we demonstrate that Mycobacterium
bovis bacillus Calmette-Gue´rin (BCG)-mediated TLR2 signaling-
induced iNOS/NO expression is obligatory for the suppression of
IFN--induced CIITA/MHC-II functions. Significantly, NOTCH/
PKC/MAPK-triggered signaling cross-talk was found critical for
iNOS/NO production. NO responsive recruitment of a bifunc-
tional transcription factor,KLF4, to thepromoter ofCIITAduring
M. bovis BCG infection of macrophages was essential to orches-
trate the epigenetic modifications mediated by histone methyl-
transferase EZH2ormiR-150 and thus calibrateCIITA/MHC-II
expression. NO-dependent KLF4 regulated the processing and
presentation of ovalbumin by infected macrophages to reactive
T cells. Altogether, our study delineates a novel role for iNOS/
NO/KLF4 in dictating the mycobacterial capacity to inhibit
CIITA/MHC-II-mediated antigen presentation by infected
macrophages and thereby elude immune surveillance.
Pathogenic mycobacteria like Mycobacterium tuberculosis
and Mycobacterium bovis have been attributed to induce sub-
stantial morbidity and mortality all over the world (1–3).
Although many species of mycobacteria elicit T cell-mediated
cytokine responses such as IFN-, the mounted immune
response is able to contain, but not eliminate the infection (4).
This is due to a series of immune evasion strategies employed by
the pathogenicmycobacteria that strongly interfere in the func-
tion of the macrophages, a critical necessity for ensuing robust
host innate and adaptive immunity (5–7). IFN-, an important
cytokine produced during infection with pathogenic mycobac-
teria induces the expression of diverse sets of immune genes in
macrophages (8). Among these, up-regulation of major histo-
compatibility complex class II (MHC-II) and members of anti-
gen processing machinery by IFN- play an important role in
resulting CD4 T cell-dependent adaptive immunity (9, 10).
Importantly, IFN- null mice are readily susceptible to myco-
bacterial infections as macrophages display diminished activa-
tion and expression of inducible nitric-oxide synthase (iNOS)/
nitric oxide (NO) (11, 12). Furthermore, human subjects
deficient for IFN- receptor or IFN- exhibit heightened sus-
ceptibility to pathogenic mycobacterial infections (13). How-
ever, macrophages infected with mycobacteria are known to
become unresponsive to effects of IFN-. This selective refrac-
toriness of macrophages involve significant inhibition of IFN-
-triggered expression of a subset of genes including class II
transactivator (CIITA),3 a crucial transcription factor required
for expression of MHC-II as well as H-2M or invariant chain
(14, 15). In this context, engagement of Toll-like receptor (TLR)
2 by pathogenic mycobacteria or cell wall antigens could con-
tribute as an early receptor proximal molecular event underly-
ing mycobacteria-mediated inhibition of IFN- responses.
iNOS is an immunomodulatory gene regulated by pathogen-
induced TLR2 signaling that determines the outcome of infec-
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tion (16, 17). iNOS catalyzing the formation of a reactive nitro-
gen intermediate, NO, along with other reactive intermediates,
mounts a potent immune response against pathogenic myco-
bacteria, aiding in the effective containment of infection (18,
19). Importantly, in addition to its antimicrobial properties,NO
modulates a wide range of signaling cascades in different cell
types by nitration, nitrosation, and nitrosylation of key signal-
ingmolecules. Suchmodulations have significant effects on fac-
tors that regulate cell-fate decisions of macrophages or den-
dritic cells during the course of infection with pathogenic
mycobacteria (20–24). Thus, mycobacterial infection-trig-
gered expression of iNOS/NO production assumes critical
importance. Apart from the numerous functions attributed to
NO in the cellular signaling, its role in antigen presentation has
rather been context dependent, whereinNOcan induce or inhibit
antigenpresentationdependinguponthecytokinemilieu (25–28).
Nevertheless, the role ofNO in regulating a crucial immunological
process like IFN--induced CIITA/MHC-II expression remains
elusive. Furthermore, the molecular mechanisms involved in
mycobacteria-induced iNOS expression andNOproduction have
been inadequately addressed.
In view of these observations, we characterized molecular
mechanisms that contribute to mycobacteria responsive down-
regulation of IFN--triggered expression of MHC-II and CIITA.
This study provides evidence that M. bovis bacillus Calmette-
Gue´rin (BCG)-mediated TLR2 signaling triggers iNOS/NO
production, which negatively regulates IFN--induced
CIITA and MHC-II expression. Deficiency in IFN--induced
CIITA or MHC-II expression requires dynamic cross-talk
among NOTCH-PKC-p38-NF-B signaling pathways. Impor-
tantly, NO-induced expression of KLF4 during M. bovis BCG
infection acts as a crucial regulatory switch to inhibit CIITA or
MHC-II expression by directing epigenetic modifications
mediated by EZH2 at the CIITA promoter and post-transla-
tional regulation of CIITA mRNA by miR-150. As a conse-
quence, infection-induced expression of KLF4 negatively regu-
lates antigen processing and presentation of ovalbumin by M.
bovis BCG-infected macrophages to antigen-specific T cells.
Collectively, these findings identify novel roles for NO/KLF4
to be what we propose as significant regulators of host-my-
cobacterial interactions.
EXPERIMENTAL PROCEDURES
Cells andMice—Macrophages were isolated from peritoneal
exudates of BALB/c, C57BL/6, or iNOS/micemaintained in
a central animal facility at the Indian Institute of Science. The
experiments with mice were carried out after the approval from
the Institutional Ethics Committee for animal experimentation as
well as the Institutional BiosafetyCommittee.MurineRAW264.7
macrophage-like cell lines (Obtained from National Center for
Cell Sciences, Pune, India) were cultured in DMEM (Invitrogen)
supplemented with 10% heat-inactivated FBS (Sigma).
Bacteria—M. bovis BCG Pasteur 1173P2 was grown to mid-
log phase in Sauton’s medium. Batch cultures were aliquoted
and stored at 70 °C. Representative vials were thawed and
enumerated for viable colony forming units on Middlebrook
7H10 agar (Difco) supplemented with OADC (oleic acid, albu-
min, dextrose, and catalase). Single-cell suspensions of myco-
bacteria were obtained by short pulses of sonication and used at
10 multiplicity of infection unless indicated.
Reagents and Antibodies—General laboratory chemicals
were purchased from Sigma, Promega, or Merck (Germany).
Anti-Thr180/Tyr182 phospho-p38 MAPK, anti-p38 MAPK,
anti-Thr183/Tyr185 phospho-SAPK/JNK MAPK, anti-SAPK/
JNKMAPK, anti-NF-B p65, anti-Thr505 phospho-PKC, anti-
PKC, anti-cleaved Notch1 (Val1744), anti-EZH2, and anti-
H3K27me3 antibodies were purchased from Cell Signaling
Technology. Anti-Notch1 (C-20) was procured from Santa
Cruz Biotechnology. Anti--ACTIN (AC-15), anti-iNOS, and
anti-CIITAantibodieswere obtained fromSigma, anti-KLF4 anti-
bodywasobtained fromImgenex, anti-MHC-II-FITC-conjugated
antibody was purchased from Miltenyi Biotec (Germany), 4,6-
diamidino-2-phenylindole (DAPI) was fromSigma. Anti-prolifer-
ating cell nuclear antigen was purchased from Calbiochem. IL-2
ELISA kit was purchased from PeproTech.
Treatment with Pharmacological Reagents—All the pharma-
cological inhibitorswere obtained fromCalbiochemand recon-
stituted using sterile DMSO (Sigma) or sterile H2O and used at
the following concentrations: -secretase inhibitor-I (GSI-I)
(10 M), chelerythrine (1 M), PKC inhibitor (Safingol) (50
M), PKC inhibitor (Rottlerin) (10M), PKC inhibitor (PKC
pseudosubstrate inhibitor, myristoylated) (5 M), PKC inhib-
itor (V2 peptide) (50 M), SB203580 (20 M), U0126 (10 M),
SP600125 (50 M), BAY 11-7082 (20 M), HMTase inhibitor (5
M), and 1400W (100 M). 0.1% DMSO was used as vehicle
control. In all experiments with inhibitors, a tested concentra-
tion was used after careful titration experiments assessing the
viability of the macrophages using a 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide assay. The cells were
treated with inhibitor for 60 min before experimental treat-
ment. NO donor, 3-morpholinosydnonimine (SIN1) (Sigma),
was used as indicated in the experiments.
Transfection Studies—RAW 264.7 cells were transfected
with 100 nM siRNA or miRNA mimic using Oligofectamine
(Invitrogen) according to the manufacturer’s instructions.
Transfection efficiency was more than 50% throughout all
experiments as determined by counting the number of siGLO
Lamin A/C positive cells in a microscopic field using a fluores-
cent microscope. 48 h post-transfection, the cells were treated
as indicated and processed for analysis. siRNA specific to
Notch1, Klf4, control siRNA, and siGLO Lamin A/C were
obtained from Dharmacon as siGENOMETM SMART pool
reagents, which contains a pool of four different double-
stranded RNA oligonucleotides. RAW 264.7 cells were tran-
siently transfected with TLR2 DN, PKC DN, KLF4 DN, and
KLF4 pcDNA3.1 constructs using low Mr polyethylenimine
(Sigma). 48 h post-transfection, the cells were treated or
infected as indicated and processed for analysis.
RNA Isolation and Quantitative Real-time RT-PCR—Total
RNA from infected or treatedmacrophages was isolated by TRI
Reagent (Sigma) as per themanufacturer’s protocol. The cDNA
synthesis kit (Bioline, UK) was used for reverse transcription
according to the manufacturer’s protocol. Quantitative real-
time RT-PCR amplification (Applied Biosystems) using the
SYBR Green PCR mixture (KAPA Biosystems) was performed
for quantification of target gene expression. All reactions were
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repeated at least three times independently to ensure reproduc-
ibility of the result. Amplification of the housekeeping gene
Gapdhwas used as an internal control and the primers utilized
are listed in supplemental Table S1.
Quantification of miRNA Expression—For detection of miR-
150, total RNA was isolated from infected or treated macro-
phages using the TRI Reagent (Sigma). Quantitative real-time
RT-PCR for miR-150 was performed using TaqMan miRNA
assays (Applied Biosystems) as per the manufacturer’s instruc-
tions. U6 snRNA was used for normalization.
Immunoblotting Analysis—Cells were lysed in RIPA buffer
constituting 50 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 0.25
mM sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM
PMSF, 1g/ml of aprotenin, leupetin, pepstatin, 1mMNa3VO4,
and 1 mM NaF. Whole cell lysate was collected and equal
amounts of protein from each cell lysate was subjected to SDS-
PAGE and transferred onto polyvinylidene difluoride mem-
branes (Millipore) by the semi-dry transfer (Bio-Rad) method.
Nonspecific binding was blocked with 5% nonfat drymilk pow-
der in TBST (20 mM Tris-HCl, pH 7.4, 137 mM NaCl, and 0.1%
Tween 20) for 60 min. The blots were incubated overnight at
4 °C with primary antibodies in 5% BSA (in TBST). After wash-
ing in TBST, blots were incubated with anti-rabbit or anti-
mouse IgG secondary antibodies conjugated to HRP in 5% BSA
(in TBST) for 2 h. After further washing in TBST, the immuno-
blots were developed with an enhanced chemiluminescence
detection system (PerkinElmer Life Sciences) as per the manu-
facturer’s instruction. -ACTIN was used as loading control.
Nuclear andCytosolic Subcellular Fractionation—Cells were
treated as indicated, gently lysed in ice-cold Buffer A (10 mM
HEPES, pH 7.9, 10mMKCl, 0.1mMEDTA, 0.1mMEGTA, 1mM
DTT, and 0.5 mM PMSF). After incubation on ice for 15 min,
the cell membrane was disrupted with 10% Nonidet P-40 and
nuclear pellets were recovered by centrifugation at 13,000 g for
15min at 4 °C. The supernatants from this stepwere used as cyto-
solic extracts. The nuclear pellet were lysedwith ice-cold Buffer C
(20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA,1 mM EGTA, 1
mM DTT, and 1 mM PMSF) and nuclear extracts were collected
after centrifugation at 13,000 {times] g for 20min at 4 °C.
Measurement of NO—To measure the amount of NO pro-
duced,macrophageswere treated as indicated. At the end of the
experiment, culture supernatants were subjected to assay for
NO production using Greiss reagent (Promega) according to
manufacturer’s instructions.
Immunofluorescence—For immunofluorescence studies, peri-
toneal macrophages or RAW 264.7 macrophages were seeded on
coverslips. After the indicated treatment, cells were fixed with
3.7% paraformaldehyde for 15min and stainedwith primary anti-
body anti-MHC class II-FITC in the dark for 1 h at room temper-
ature. Nuclear staining was done using DAPI (1g/ml) for 5min.
Coverslips were mounted on a slide with glycerol and confocal
imageswere takenonZeissLSM710Meta confocal laser scanning
microscope using plan-Apochromat 63/1.4 Oil DIC objective
and images were analyzed using ZEN 2009 software.
Chromatin Immunoprecipitation (ChIP)—ChIP assays were
carried out using the protocol provided by Upstate Biotechnol-
ogy, with certain modifications. Briefly, macrophages were
fixed with 1.42% formaldehyde for 15min at room temperature
followed by inactivation of formaldehyde with addition of 125
mM glycine. Nuclei were isolated from macrophages using
modifiedRIPAbuffer containing 1%TritonX-100 and chroma-
tin was sheared using a cup sonicator (Sonics and Materials,
Inc.). Chromatin extracts containing DNA fragments with an
average size of 500 bp were immunoprecipitated using specific
antibodies or rabbit preimmune sera. Purified DNA was ana-
lyzed by quantitative real-time RT-PCR. All results were nor-
malized to amplification of 28 S rRNAand all ChIP experiments
were repeated at least three times and the primers utilized are
listed in supplemental Table S1.
Immunoprecipitation (IP)—IP assays were carried out using
protocolprovidedbyMillipore,withcertainmodifications.Briefly,
macrophages were gently lysed in ice-cold RIPA buffer on an
orbital shaker. The cell lysates were incubated with anti-KLF4,
anti-EZH2, or rabbit preimmune sera at 4 °C for 2 h on an orbital
shaker. The immunocomplexes were captured using Protein
A-agarose at 4 °C for 2 h. The beads were harvested, washed, and
boiled in 5 Laemmli buffer for 10 min. The samples were sepa-
rated by SDS-PAGE and further subjected for immunoblotting.
EZH2 Activity in Vivo—Phosphate-buffered saline (PBS) as
vehicle control or 106M. bovis BCGwas injected intravenously
into the tail vein of mice. After 4 days of infection, mice were
sacrificed, and spleen and lymph nodes were collected. Alter-
natively, mice were infected intraperitoneally with 106M. bovis
BCG for 12 h and peritoneal macrophages were isolated. Each
in vivo experiment involved 4 animals per group. The cells
obtained from spleen, lymph node, and peritoneal exudates
were utilized for ChIP experiments.
Antigen Presentation Assay—Peritoneal macrophages or
RAW264.7 cells were seeded in 96-well flat-bottom plates (5
105 cells/well). In the experiments involving RAW 264.7 cells,
transient transfectionwas carried out using KLF4 pcDNA3.1 or
KLF4 DN or pcDNA3.1 alone. After 48 h, cells were infected
with 10:1 multiplicity of infection ofM. bovis BCG for 12 h and
then incubated with IFN- (100 ng/ml) as indicated. Further-
more, the cells were treatedwith ovalbumin (500g/ml) for 6 h,
washed, and incubated with splenocytes (1.5  106 cells/well)
obtained from C57BL/6 (H-2b) or BALB/c (H-2d) mice in case
of experiments with peritoneal macrophages from C57BL/6
(H-2b) mice or RAW 264.7 (H-2d) macrophages, respectively.
The splenocytes used were obtained frommice that were intra-
venously challenged with 500 g/ml of ovalbumin for 5 days.
Macrophages-splenocytes were co-cultured for 48 h and cul-
ture supernatants were utilized for IL-2 ELISA.
Enzyme Immunoassay—Enzyme immunoassayswere carried
out in 96-well microtiter plates (Nunc, USA) using cell-free
culture supernatant. Sandwich ELISAwas performed as per the
manufacturer’s instructions. Briefly, assay plates were incu-
bated with capture antibody at 4 °C overnight. After blocking
with 1%BSA for 1 h at 37 °C, wells were incubatedwith cell-free
supernatants for 2 h and then with biotinylated detection anti-
body for 2 h at 37 °C. The wells were further incubated with
streptavidin-HRP for 1 h at 37 °C and developed with 3,3,5,5-
tetramethylbenzidine. The absorbance was measured at 450
nm using an ELISA reader (Molecular Devices).
Statistical Analysis—Levels of significance for comparison
between samples were determined by the Student’s t test distri-
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bution and one-way ANOVA. The data in the graphs are
expressed as themean S.E. and p 0.05 were defined as signif-
icant.GraphPadPrism3.0software (GraphPadSoftware)wasused
for all statistical analysis. The representative immunoblots were
quantified by the Multi Gauge version 2.3 application (Fujifilm
Medical Systems), using profile lane quantification with band
detection and subtraction of respective background.
RESULTS
NO Regulates M. bovis BCG-mediated Inhibition of IFN--
induced MHC-II Expression—Induced expression of iNOS in
macrophages upon infection with various pathogenicmicrobes
often acts as a keymediator to regulate the initiation andmain-
tenance of kinetics of ensuing protective immunity (29). In
addition to its antimicrobial attributes, iNOS/NO modulate a
wide range of signaling cascades that can have significant bear-
ings on built-in regulatory circuits that control cell-fate deci-
sions of macrophages during the course of infection with
pathogenic mycobacteria (17, 30). In view of above men-
tioned observations, we explored a role for iNOS/NO in the
ability of the M. bovis BCG to down-regulate MHC-II
expression in macrophages. As shown in Fig. 1, A and B, and
supplemental Fig. S1,A andB,M.bovisBCG infection critically
abrogated IFN--induced MHC-II expression both at tran-
script and protein levels in macrophages.
Antigen processing involving MHC-II is tightly regulated by
a key transcription factor, CIITA. Mice deficient for CIITA
exhibit a marked reduction in MHC-II expression (31). Myco-
bacteria or its antigens that reduce MHC-II expression have
been demonstrated to involve inhibition of CIITA expression
(15, 31, 32). As shown, M. bovis BCG infection significantly
down-regulated IFN--induced CIITA expression levels (Fig.
1C and supplemental Fig. S1C). Next, we assessed the role for
FIGURE 1.M. bovis BCG-mediated inhibition of IFN--induced MHC-II/CIITA requires NO. A, mouse peritoneal macrophages were infected withM. bovis
BCG for 12h followedby100ng/ml of IFN- treatment for 12h andMHC-IImRNAexpressionwas analyzedbyquantitative real-timeRT-PCR.B andC, peritoneal
macrophageswere infectedwithM.bovisBCG for 12hprior to treatmentwith10or 100ng/mlof IFN- for 12h. Expression levels ofMHC-II (B) andCIITA (C)were
analyzed by immunoblotting. MHC-II and CIITA expression over -ACTIN was quantitated. D-F, peritoneal macrophages from WT or iNOS/ mice were
infected with M. bovis BCG (multiplicity of infection 10), or in panel F, treated with NO donor SIN1 followed by treatment of 100 ng/ml of IFN-, mRNA (D)
expression of MHC-II was examined by quantitative real-time RT-PCR andMHC-II (E) and CIITA (F) protein expression levels were checked by immunoblotting.
G, macrophages were pretreated with 1400W, an inhibitor of iNOS, for 1 h prior to infection withM. bovis BCG for 12 h followed by treatment with 100 ng/ml
of IFN- for 12 h. CIITA protein levelswere examined using immunoblotting.H, peritonealmacrophageswere treatedwith SIN1 at the indicated concentration
for 12h, followedby IFN- treatment for 12h.MHC-II andCIITAexpressionwas analyzedby immunoblotting. I,WTor iNOS/macrophageswere infectedwith
M. bovis BCG or SIN1 for 12 h followed by treatment of 100 ng/ml of IFN- for 48 h and surface expression of MHC-II was assessed by immunofluorescence
microscopy. Representative images are shown (n 3). All blots shown are representative of 3 independent experiments. Quantitative real-time RT-PCR data
represent mean S.E., n 3. DMSOwas used as vehicle control.Med, medium;WT, wild type; iNOS/, iNOS knock out. *, p 0.005, as compared with IFN-
treated cells and **, p 0.005, as compared with WT IFN- BCG-treated/infected cells (one-way ANOVA). Bar, 10 m.
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iNOS/NO duringM. bovis BCG-mediated subdued expression
of CIITA or MHC-II. Infection of macrophages derived from
iNOS null mice, but not WT mice, exhibited a marked defi-
ciency to down-regulate MHC-II and CIITA expression (Fig.
1, D–F). Furthermore, pretreatment of macrophages with
1400W, an iNOS activity inhibitor, severely reduced the
capacity of the M. bovis BCG to inhibit CIITA expression
(Fig. 1G). Additionally, treatment of macrophages with a NO
donor like 3-morpholinosydnonimine (SIN1) was sufficient
to abrogate the IFN--induced MHC-II expression, validat-
ing the crucial role of NO in CIITA expression (Fig. 1, F and
H). As illustrated in Fig. 1I, surface expression of MHC-II
during M. bovis BCG infection was compromised despite
IFN- treatment in WT macrophages but iNOS null macro-
phages failed to do so. Further corroborating the observation
that SIN1 failed to induce surface expression ofMHC-II with
IFN- treatment emphasizing the iNOS/NO-dependent
CIITA/MHC expression.
M. bovis BCG-triggered TLR2-NOTCH Signaling Pathways
Control the Expression of iNOS/NO—Reports have shown that
extensive exposure of macrophages to 19-kDa antigens of M.
tuberculosis inhibits MHC-II expression in a TLR2-dependent
manner. Accordingly, macrophages from TLR2 or Myd88
knock-out mice failed to exhibit mycobacteria or 19-kDa anti-
gen-induced inhibition of MHC-II-mediated antigen process-
ing (14, 15). Interestingly, TLR2-triggered signaling cascades
during mycobacterial infection regulates iNOS expression and
NO production (17, 33). In this perspective, kinetic analysis
demonstrated M. bovis BCG-induced expression of iNOS and
NO production in a time- or CFU-dependent manner (supple-
FIGURE 2. M. bovis BCG activates NOTCH1 to mediate iNOS/NO production and suppression of CIITA/MHC-II molecules. A and B, WT or TLR2 null
peritoneal macrophages were assessed for iNOS expression (A) by immunoblotting after infection withM. bovis BCG for 6 h and NO production (B) by Greiss
reagent after infectionwithM.bovisBCG for 12h.C,WTor TLR2nullmacrophageswere infectedwithM.bovisBCG for 12handNOTCH1activationwasanalyzed
by immunoblotting.D, macrophages were pretreated with GSI-I (NOTCH activation inhibitor) for 1 h and infected withM. bovis BCG for 6 h to determine iNOS
expression by immunoblotting. E, immunoblot for iNOS expression with M. bovis BCG infection for 6 h in RAW 264.7 macrophages transfected with Notch1-
specific siRNA. F, peritoneal macrophages were pretreatedwith GSI-I for 1 h and then infectedwithM. bovis BCG for 12 h followed by IFN- treatment for 12 h.
MHC-II expression was assessed by immunoblotting. G, representative immunofluorescence images (n 3) stained for surface MHC-II on murine RAW 264.7
macrophages pretreated with GSI-I for 1 h followed byM. bovis BCG infection for 12 h and 100 ng/ml of IFN- treatment for 48 h. H, peritoneal macrophages
were pretreated with GSI-I for 1 h and then infected/treated with M. bovis BCG or with SIN1 as indicated for 12 h followed by IFN- treatment for 12 h. The
expression level of CIITAwas determinedby immunoblotting. I and J, murine RAW264.7macrophages transfectedwithNT orNotch1 siRNAwere infectedwith
M. bovisBCG for 12 hprior to IFN- treatment. Quantitative real-timeRT-PCR (I) and immunoblotting (J) was performed to analyze CIITA andMHC-II expression.
K, representative immunofluorescence images (n 3) stained for surface MHC-II on murine RAW 264.7 macrophages transfected with Notch1-specific siRNA,
followedbyM.bovisBCG infection for 12hand100ng/mlof IFN- treatment for 48h.All blots shownare representativeof 3 independent experiments.NOdata
representmean S.E., n 3.Med, medium;WT, wild type; TLR2/, TLR2 knock out;NT, non-targeting. ***, p 0.005, as comparedwithM. bovis BCG-infected
WTcells; *,p0.005, as comparedwith IFN--treatedNT siRNA-transfected cells; **,p0.05, as comparedwith IFN-BCG-treatedNT siRNA transfected cells
(one-way ANOVA). Bar, 10 m.
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mental Fig. S2, A–C). Furthermore, macrophages from TLR2
null mice displayed compromised ability to induce iNOS
expression or NO production (Fig. 2, A and B). Similarly, the
TLR2 dominant-negative (DN) construct significantly reduced
M. bovis BCG responsive iNOS expression or NO production
(supplemental Fig. S2, D and E).
NO often executes key cell-fate decisions in various cellular
contexts by modulating several signaling pathways in the host
cells (34). Hence, signaling events that regulate iNOS/NO
expression could act as a rate-limiting step during M. bovis
BCG infection-triggered inhibition ofMHC-II or CIITA. Inter-
estingly, TLR2- dependent activation of NOTCH1 is known to
induce activation of several proinflammatory cytokines and
enzymes such as iNOS and COX-2 (17, 35). In this context, we
addressed the role for the TLR2-mediated NOTCH1 signaling
pathway in regulating iNOS/NO expression. Mycobacterial
species, in addition to selected antigens, are known to induce
NOTCH1 signaling in macrophages as assessed by the genera-
tion of the cleaved product of NOTCH1, notch intracellular
domain, or expression of NOTCH1 signaling target genes or
cognate ligands (36, 37). As a proof of concept we analyzed the
generation of the activation marker of NOTCH1 signaling, the
notch intracellular domain (supplemental Fig. S2F). Accord-
ingly, M. bovis BCG triggered the activation of NOTCH1 sig-
naling in WT, but not in TLR2 null macrophages (Fig. 2C).
Importantly, inhibition of NOTCH1 signaling activation by the
pharmacological inhibitor GSI-I or by siRNA-reducedM. bovis
BCG-induced iNOS expression and NO production (Fig. 2, D
and E, and supplemental Fig. S2,G–I). Supporting these obser-
vations, both immunoblotting and immunofluorescence stud-
ies demonstrated that abrogation of NOTCH1 signaling
significantly compromised the capacity of M. bovis BCG to
FIGURE 3.NOTCH/PKC axis regulatesMAPKandNF-BduringM. bovisBCG-mediated iNOS expression andNOproduction.A, peritonealmacrophages
were treated with PKC isoform inhibitors for 1 h prior to infection withM. bovis BCG for 6 and 12 h, iNOS expression was assessed using immunoblotting and
NO production in the cell-free supernatant was estimated by Griess reagent, respectively. B, inhibition of NOTCH1 activation by GSI-I was carried out 1 h prior
toM. bovis BCG infection and activation of PKC as determined by immunoblotting. C, pretreatment of macrophages withMAP kinase inhibitors, U0126 (MEK
inhibitor), SB203580 (p38 inhibitor), andSP600125 (JNK1/2 inhibitor) for 1h followedby infectionwithM.bovisBCG for 6 and12h toassay iNOSexpressionwith
immunoblotting and NO production in the supernatant by Griess reagent, respectively. D, activation of p38 and JNK1/2 MAPK was analyzed by immunoblot-
ting in macrophages treated with GSI-I prior to infection withM. bovis BCG. E,M. bovis BCG-induced iNOS expression as analyzed by immunoblotting and NO
production as assayed using Greiss reagent in peritoneal macrophages treated with NF-B activation inhibitor (BAY 11-7082). F, immunoblotting for nuclear
localization of p65NF-B in peritonealmacrophages infectedwithM. bovis BCG in the presence of GSI-I, chelerythrine, PKC inhibitor, SB203580, or SP600125.
G, murine RAW 264.7 macrophages transfected with Notch1 siRNA were infected with M. bovis BCG and analyzed for PKC-MAPK-NF-B activation by immu-
noblotting. All blots shown are representative of 3 independent experiments. NO data represent mean S.E., n 3. DMSOwas used as vehicle control.Med,
medium. *, p 0.05, as compared withM. bovis BCG-infected cells (one-way ANOVA).
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down-regulate MHC-II and CIITA expression (Fig. 2, F–K). In
accordance with the above mentioned observation, the NO
donor SIN1 was unable to inhibit IFN--induced CIITA
expression upon blockade of NOTCH1 signaling activation by
GSI (Fig. 2H, right panel). These results suggest that M. bovis
BCG-triggered TLR2/NOTCH1 signaling pathways hold the
capacity to modulate iNOS/NO production to regulate CIITA/
MHC-II expression.
NOTCH1-dependent PKC-MAPK-NF-B Signaling Axis
Regulates iNOS Expression and NO Production duringM. bovis
BCG Infection—To further delineate signaling events involved
inM. bovis BCG-mediated NOTCH1-NO-triggered regulation
of MHC-II and CIITA, we assayed the role for protein kinase C
(PKC) isoforms, mitogen-activated protein kinase (MAPK),
and transcription factor nuclear factor-B (NF-B). PKCs often
act as rate-limiting kinases in orchestrating wide ranging func-
tions in immune cells. For example, strong correlates exist
between NOTCH1 and PKCs, PKCs in regulating MAPK acti-
vations etc. (5, 36). In this perspective, a screen with isoform-
specific inhibitors was carried out to identify a role for the spe-
cific isoform of PKC in regulating iNOS expression during M.
bovis BCG infection. As shown, inhibition of PKC activity
showed profound reduction in iNOS expression and NO pro-
duction (Fig. 3A). Notably, infection with M. bovis BCG dem-
onstrated kinetics of PKC activation in a time-dependent
manner and the PKCDN construct critically reducedM. bovis
BCG-induced iNOSexpression orNOproduction (supplemen-
tal Fig. S3, A–C). Furthermore, perturbation ofM. bovis BCG-
induced NOTCH1 signaling resulted in a significant inhibition
of PKC activation (Fig. 3B).
FIGURE 4.NO-mediated activation of KLF4 suppresses IFN--inducedMHC-II/CIITA expression. A and B, mouse peritoneal macrophages were infected/
treated withM. bovis BCG (A) or SIN1 (B) 12 h prior to IFN- treatment at the indicated time points and total expression levels of KLF4 protein were assayed by
immunoblotting. C, WT or iNOS nullmacrophageswere either infectedwithM. bovis BCGor treatedwith SIN1 for 12 h followedwith treatmentwith 100 ng/ml
of IFN- for 12 h. Differential KLF4 expressionwas analyzed by immmunoblotting.D, ChIP assay was performed using anti-KLF4 or anti-IgG antibody usingWT
or iNOSnullmacrophages infectedwithM.bovisBCG.Recruitmentof KLF4at twosites atCIITApromoter (563and1251 from1 site)wasdeterminedusing
quantitative real-time RT-PCR. E and F, murine RAW 264.7 macrophages were transiently transfected with pcDNA3.1 or KLF4 overexpressed 48 h followed by
infection with M. bovis BCG for 12 h and IFN- treatment for the next 48 or 12 h; E, quantitative real-time RT-PCR for CIITA and MHC-II expression, and F,
immunoblotting for CIITA expression.G-I, macrophageswere transfectedwith Klf4 siRNA and treated similarly to panel E.G andH, CIITA andMHC-II expression
analysis by quantitative real-time RT-PCR and immunoblotting. I, representative immunofluorescence images are shown (n 3). All blots shown are repre-
sentative of 3 independent experiments. Quantitative real-time RT-PCR data represent mean S.E., n 3. DMSO was used as vehicle control.Med, medium;
WT, wild type; iNOS/, iNOS knock out; OE, overexpression; NT, non-targeting. ***, p 0.005, as compared withM. bovis BCG infected WT cells; *, p 0.005,
as compared with IFN--treated pcDNA3.1 or NT siRNA transfected cells; **, p  0.05, as compared with IFN-  BCG-treated NT siRNA-transfected cells
(one-way ANOVA). Bars, 10 m.
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TLR2/NOTCH1 signaling pathways often require the activa-
tion ofMAPKs formodulation of transcription factors that reg-
ulate downstream genes to mediate a variety of cellular func-
tions (35). Moreover, several reports have demonstrated PKC
as an important regulator of MAPKs (38, 39). Thus, we assayed
the role for PKC-triggered MAPK-NF-B activation during
infection-induced expression of iNOS/NO. Signaling perturba-
tions with MAPK-specific inhibitors, U0126 (MEK inhibitor),
SB203580 (p38 inhibitor), and SP600125 (JNK1/2 inhibitor),
ascertained that the inhibition of p38 and JNK1/2, but not
ERK1/2 reduced M. bovis BCG-induced iNOS expression and
NOproduction (Fig. 3C). In these lines, we confirmed the infec-
tion-triggered activation of p38 and JNK1/2 in macrophages
(supplemental Fig. 3D). Furthermore, treatment of macro-
phages with GSI (NOTCH activation inhibitor), chelerythrine
(pan-PKC inhibitor), or Rottlerin (PKC inhibitor) impaired
the activation ofM. bovis BCG-mediated p38 and JNK1/2 (Fig.
3D and supplemental Fig. 3C).
NF-B acts as a key regulator of important cellular and
immunological functions across various cell types. Mycobacterial
infection-triggered TLR2/NOTCH1 signaling pathways are
known to activate NF-B (36, 40). Furthermore, the iNOS pro-
moter contains several binding sites for cis acting elements includ-
ing that of NF-B. In accordance with published reports,M. bovis
BCG infection led to time-dependent increments inNF-B trans-
location from the cytosol to the nucleus scoring the activation of
NF-B (supplemental Fig. S3F). To ascertain the role forNF-B in
inducing iNOS expression or NO production, we utilized the
pharmacological inhibitor of NF-B activation, BAY 11-7082. As
shown, BAY 11-7082 significantly reducedM. bovis BCG-driven
iNOS/NO expression, and inhibition of NOTCH signaling (GSI),
pan-PKC (chelerythrine), PKC (Rottlerin), p38 (SB203580) but
FIGURE 5. KLF4mediates histonemodification at the CIITA promoter to down-regulate IFN--inducedMHC-II/CIITA. A–F, ChIP assays were performed
using anti-EZH2 or anti-H3K27me3 or anti-IgG antibody using macrophages infected with M. bovis BCG and/or transfected with the KLF4 overexpression
construct or Klf4 siRNA. A, C, and E, recruitment of EZH2; and B,D, and F, presence of H3K27me3 at KLF4 binding sites on the CIITA promoter (563 and1251
from1 site) was determined using quantitative real-time RT-PCR. G, peritoneal macrophages were infected withM. bovis BCG for 12 h, immunoprecipitated
with anti-KLF4 and anti-EZH2 antibodies, and analyzed for interaction using immunoblotting. H and I, macrophages were pretreated with HMTase (histone
methyltransferase) inhibitor for 1 h followed byM. bovis BCG infection for 12 h and IFN- treatment for the next 12 and 48 h;H, immunoblots for the indicated
molecules; and I, representative immunofluorescence images (n  3) for MHC-II surface expression. All blots shown are representative of 3 independent
experiments. Quantitative real-time RT-PCR data represent mean  S.E., n  3. DMSO was used as vehicle control. Med, medium; OE, overexpression; NT,
non-targeting; IB, immunoblotting. *, p 0.005, as compared with NT,M. bovis BCG infected cells (one-way ANOVA). Bar, 10 m.
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not JNK1/2 (SP600125)markedly compromised theM.bovisBCG
driven NF-B translocation to the nucleus (Fig. 3, E and F). Sub-
stantiating the pharmacological inhibitor data, perturbation ofM.
bovisBCG-inducedNOTCH1signalingbyNotch1-specific siRNA
resulted in a significant decrease in the infection-induced PKC,
p38, JNK1/2 activation, and NF-B translocation from cytosol to
nucleus (Fig. 3G).
Characterization of KLF4-mediatedRegulation ofCIITAdur-
ing Infection with M. bovis BCG—As discussed, the M. bovis
BCG-triggered TLR2/NOTCH1 signaling pathway is necessary
for NO production that in turn interferes with IFN--mediated
responses in macrophages including the induced CIITA and
MHC-II expression. However, the molecular regulatory switch
that controls TLR2/NOTCH/iNOS/NO-mediated down-regu-
lation of IFN--induced CIITA expression remains unex-
plored. In this context, the altered promoter activity of CIITA
duringM. bovis BCG infection of macrophages could critically
contribute to abrogation of CIITA expression during infection.
Bioinformatic analysis for possible transcription factors bind-
ing to the CIITA promoter using the MatInspector program
(Software of genomatix, www.genomatix.de) predicted two
binding sites for a novel transcription factor, Krüppel-like fac-
tor (KLF) 4 in the CIITA promoter. KLF4 belongs to a subclass
of the zinc finger family ofDNAbinding transcriptional factors,
which execute varied effects on cellular reprogramming of
macrophages either by suppressing or activating promoters of
the immune genes (41–44).
To analyze the role of KLF4 in the current study, we evalu-
ated infection-induced expression of KLF4 and as shown in Fig.
4A, M. bovis BCG significantly induced KLF4 expression in a
time-dependent manner. However, IFN- treatment alone
failed to induce considerable levels of KLF4 expression. Inter-
estingly, SIN1, a pharmacological NO donor, induced KLF4
expression in macrophages in a similar time-dependent man-
ner (Fig. 4B). Emphasizing a crucial function of NO in regulat-
ing KLF4,macrophages from iNOS null mice exhibitedmarked
deficiency in inducing KLF4 upon infection withM. bovis BCG,
which could be rescued by addition of SIN1 (Fig. 4C). These
results strongly advocated a role for NO during M. bovis BCG
infection-mediated expression of KLF4. To further explore the
function for NO-KLF4 signaling, we preformed ChIP experi-
ments and demonstrated that infection with M. bovis BCG
resulted in significant recruitment of KLF4 at the respective
sites of the CIITA promoter (Fig. 4D). Corroborating these
results, the CIITA promoter in iNOS null macrophages dis-
played a reduction in KLF4 recruitment. Furthermore, we car-
ried out gain-of-function and loss-of-function studies to vali-
date the role for KLF4 during infection ofmacrophages withM.
bovis BCG. Although enforced expression of KLF4 critically
reduced IFN--induced MHC-II and CIITA mRNA as well as
proteins (Fig. 4,E and F, and supplemental Fig. S4A), repression
of KLF4 by DN constructs or siRNA abolished the ability ofM.
bovis BCG to inhibit MHC-II and CIITA expression (Fig. 4,
G–I, and supplemental Fig. S4, A and B).
KLF4 Directs Epigenetic Modifications to Fine-tune CIITA
Expression—The epigenetic and chromatin modifications pro-
vide novel modes of controlling gene expression. These altera-
tions include histone modifications like acetylation, methyla-
tion, and DNAmethylation. Recently, small non-coding RNAs
like miRNAs have been classified as epigenetic modifications
that are crucial regulators of gene expression (45–47). Studies
with pathogenic mycobacteria and its cell wall antigens have
implied infection-induced epigenetic changes at the CIITA
promoter (15, 48). In the present study, we hypothesize that
FIGURE 6.M. bovis BCGmodulates EZH2 activity in vivo. A-C, ChIP analysis to determine the fold-recruitment of EZH2 and presence of H3K27me3 at KLF4
binding sites on the CIITA promoter (563 and 1251 from 1 site) in spleen (A), lymph nodes (B), or peritoneal macrophages (C) from mice that are
intravenously (A and B) or intraperitoneally (C) injectedwith PBS orM. bovis BCG. Quantitative real-time RT-PCR data representmean S.E., n 4. *, p 0.005,
as compared with PBS (t test).
NO and KLF4 Negatively RegulateMHC-II Expression
20600 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 28•JULY 12, 2013
 by guest on O
ctober 22, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
KLF4 being a novel regulator of CIITAmight render repressive
epigeneticmodifications at the CIITA promoter. Thus, we ana-
lyzed the status of H3K27 trimethylation, representing a
repressed promoter, at the CIITA promoter under the influ-
ence of KLF4. M. bovis BCG infection of macrophages led to
significantly elevated recruitment of EZH2, a histone methyl-
transferase specific to H3K27, onto the CIITA promoter at
KLF4 binding consensus sequences (Fig. 5A). Concordantly, a
marked increase in H3K27 trimethylation was observed at
corresponding sites (Fig. 5B). The role of KLF4 in modulating
histone modifications was further validated using gain-of-
function and loss-of-function approaches. KLF4-dependent
recruitment of EZH2 and subsequent H3K27 trimethylation
was affirmed (Fig. 5, C–F). As a proof of concept, a IP assay
confirmed the KLF4-EZH2 interaction (Fig. 5G). Next, the role
of EZH2 activity in modulation of IFN--induced CIITA and
MHC-II expression was analyzed. As shown in Fig. 5, H and I,
inhibition of histonemethyltransferase activity demonstrated a
marked rescue of M. bovis BCG-mediated suppression of
CIITA and MHC-II expression. In accordance to these obser-
vations, in vivo infection of M. bovis BCG through tail vein
injection showed significant increments in EZH2 recruitment
and trimethylation at the CIITA promoter in cells obtained
from spleen as well as lymph nodes (Fig. 6, A and B). Similarly,
in vivo peritoneal macrophage infection with M. bovis BCG
induced increased EZH2 activity at KLF4 binding sites on the
CIITA promoter (Fig. 6C). Altogether, these observations sug-
gest a significant contribution ofKLF4 responsive histonemod-
ifications at the CIITA promoter to arbitrate M. bovis BCG-
infected macrophage refractoriness to IFN-.
As discussed, KLF4 exhibits a dual activity of controlling cel-
lular programming either by suppressing or activating the
FIGURE7.KLF4 responsivemiR-150 targetsCIITA to subdue IFN--inducedMHC-II.A,murineRAW264.7 cellswere transfectedwith variousmiRNAmimics
as indicated and treated with 100 ng/ml of IFN- for 12 h. Immunoblotting was performed to determine the CIITA levels and quantification of the same is
shown.B, peritonealmacrophagesderived fromWTand iNOSnullmacrophageswere infectedwithM.bovisBCG for 12handassayed formiR-150using specific
primers by quantitative real-time RT-PCR. C, recruitment of KLF4 onto themiR-150 promoter inWT and iNOS null macrophages on infectionwithM. bovis BCG
was analyzed by ChIP assay. D-F, miR-150 levels were estimated in RAW 264.7 macrophages transfected with Klf4 siRNA (D), KLF4 DN (E), or KLF4 OE (F) and
infectedwithM. bovis BCG for 12 h using quantitative real-time RT-PCR.G andH, RAW264.7 cells were transfectedwithmiR-150 inhibitor (G) ormiR-150mimic
(H), and infected withM. bovis BCG in panel G, followed by treatment with IFN- for 48 h. Representative immunofluorescence images are shown (n 3). All
blots shown are representative of 3 independent experiments. Quantitative real-time RT-PCR data represent mean S.E., n 3.Med, medium;WT, wild type;
iNOS/, iNOS knock out; OE, overexpression; *, p 0.05, as compared with WT/NT/pCMVM. bovis BCG-infected cells (one-way ANOVA). Bars, 10 m.
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expression of genes (42, 44). To investigate the dichotomous
function of KLF4, we further explored the ability of KLF4 to
activate the expression of non-coding miRNAs, which in turn
could contribute to maintain the sustained suppression of
CIITA. In this perspective, the 3 UTR of CIITA was analyzed
for probablemiRNA target sites. Extensive bioinformatics anal-
yses identified the binding sites for miR-125b(1745–1753),
miR-146a(909–915), miR-150(347–354), and miR-155(187–
194) in the 3 UTR of CIITA. To confirm the role of miRNA(s)
in targetingCIITAmRNA, ectopic expression of thesemiRNAs
was performed. As shown in Fig. 7A, miR-150 but not other
tested miRNAs, abrogated CIITA expression. In accordance
with the previous data, iNOS null macrophages showed a com-
promised ability to induce elevated levels of miR-150 as com-
pared with WT macrophages (Fig. 7B). Furthermore, KLF4-
mediated miR-150 expression during M. bovis BCG infection
was substantiated using ChIP assays. miR-150 promoter analy-
sis using the MatInspector program identified 5 distinct KLF4
binding consensuses sites. Infection induced by increased
recruitment of KLF4 at the miR-150 promoter was found to be
iNOS/NO-dependent (Fig. 7C). Confirming this observation,
knockdown of KLF4 activity using specific siRNAs or expres-
sion of the KLF4 DN mutant severely reduced M. bovis BCG-
induced miR-150 expression (Fig. 7, D and E), whereas in the
presence of KLF4 overexpression, heightened miR-150 expres-
sion prevailed (Fig. 7F). The function of miR-150 during M.
bovis BCG-induced down-regulation of CIITA was supported
with analysis of surface expression of MHC-II. As illustrated in
Fig. 7,G andH, miR-150 inhibition hindered theM. bovis BCG
responsive suppression of MHC-II surface expression; on the
other hand ectopic expression of miR-150 prevented IFN--
induced MHC-II expression. Altogether, our data demon-
strated that KLF4 directs novel epigenetic mechanisms such as
H3K27 trimethylation at theCIITApromoter andmiR-150 tar-
geted CIITA expression, which are necessary to regulate
macrophage cellular programming.
KLF4 Is a Negative Regulator of IFN--induced Antigen
Processing—The adaptive immunity to mycobacterial infec-
tions involves activation and expansion of antigen-specific CD4
T cells that often culminates in elevated secretion of IL-2 (49).
In this context, modulation of MHC-II expression byM. bovis
BCG could be a rate-limiting step in ensuing adaptive immu-
nity. In view of above mentioned observation, we assessed the
role of KLF4 in regulating antigen processing and presentation
by M. bovis BCG-infected macrophages to reactive T cells. As
shown in Fig. 8A, M. bovis BCG infection significantly down-
regulated IFN--induced MHC-II-mediated processing and
presentation of an exogenous antigen, ovalbumin as assessed by
IL-2 secretion by ovalbumin reactive T cells. Importantly,
macrophages derived from iNOSnullmice remained refractory
to M. bovis BCG-mediated inhibition of ovalbumin presenta-
tion (Fig. 8B). Furthermore, overexpression of KLF4 in hap-
lotype-matchedmacrophages inhibited processing and presen-
tation of ovalbumin to reactive T cells (Fig. 8C). On the
contrary, KLF4 DN abolished the ability of M. bovis BCG to
inhibit processing andpresentation of ovalbumin toT cells (Fig.
8D). These results strongly advocate NO/KLF4 as critical reg-
ulators of antigen processing and presentation duringM. bovis
BCG infection of macrophages.
DISCUSSION
TLR2 has been implicated as a primary receptor that senses
mycobacteria and influences host resistance against the patho-
gens (50). Nevertheless, recent studies have provided contrast-
ing evidence. The pathogenic mycobacteria-induced TLR2
cascade modulates key signaling and functional molecules
FIGURE 8. NO-dependent KLF4 regulates antigen presentation in macrophages. A, antigen presentation assay was performed using peritoneal macro-
phages and splenocytes obtained fromC57BL/6mice and cell-free supernatantwas estimated for IL-2 cytokine production using enzyme immunoassay. *, p
0.05; **, p 0.005 as compared with IFN--treated cells (one-way ANOVA). B, experimental setup similar to panel Awas used to assess IL-2 levels in wild type
and iNOS null macrophages. *, p 0.005, as compared with IFN--treated cells and **, NS, as compared with wild type M. bovis BCG-infected macrophages
(one-wayANOVA).C andD, RAW264.7macrophage cellswere transiently transfectedwith KLF4overexpression (C) or KLF4DN (D) for 48h andused for antigen
presentation assay with splenocytes obtained from BALB/cmice. *, p 0.05, as comparedwith pcDNA3.1-transfected IFN--treated cells; **, NS, as compared
with pcDNA3.1-transfectedM. bovis BCG-infectedmacrophages (one-way ANOVA). Data represent mean S.E., n 3.Med, medium;WT, wild type; iNOS/,
iNOS knock out; OE, overexpression.
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involved in regulating immune responses, creating a niche for
its better survival inside the host. One such potential effect of
mycobacteria-mediated TLR2 signaling is inhibition of antigen
presentation (51). Although, few studies have unraveled the
mechanisms involved in mycobacteria-induced TLR2-medi-
ated down-regulation of CIITA and MHC-II expression, the
role of NO in such a scenario has not been adequately
addressed.Ourwork herein significantly strengthens the obser-
vation as we delineated the role of M. bovis BCG-mediated
TLR2/NOTCH1-triggeredNO in reducingMHC-II andCIITA
expression. The NO responsive transcription factor KLF4 was
found to orchestrate epigenetic modifications at the CIITA
promoter to regulate MHC-II expression.
TLR2-triggered NOTCH1 signaling activates NF-B, a key
transcription factor for numerous immunological processes
(36, 37). Interestingly, several reports indicate the involvement
of NF-B in inducing iNOS expression and that NOTCH1 sig-
naling modulates the induction of proinflammatory cytokines
(17, 35). In linewith these observations,NOTCH1 signaling has
emerged as an important regulator of iNOS/NO expression via
NF-B in mouse macrophages.
NOTCH1 signaling has been implicated to activate cellular
PKC isoforms (36). In the present context, PKC, a novel
isoenzyme is primarily activated by diacylglycerol. Interest-
ingly, the formation of diacylglycerol is due to the activation of
phospholipase C or phospholipase D and their subsequent
action on phosphatidylcholine present on the cell membrane
(52). Notably, activation of phospholipase D during M. bovis
BCG infection in macrophages has been addressed in our pre-
vious studies (37). Furthermore, PKC regulates downstream
signaling molecules and transcription factors such as MAPKs
and NF-B (39, 53). In this regard, our current study demon-
strates the involvement PKC-dependent p38 and JNK1/2, but
not ERK1/2 inM. bovis BCG-mediated induction of iNOS/NO
expression. However, JNK1/2 did not mediate NF-B activa-
tion. We speculate that JNK1/2 could activate other transcrip-
tion factors like AP-1, known to regulate iNOS expression in
other cellular contexts (54, 55).
Role of NO as intracellular messengers has been extensively
studied in several cellular contexts. Notably, NOmodulates the
activity of different transcription factors such as AP-1, EGR-1,
HIF-1, and Nrf2 (56–59). However, the ability of NO to regu-
FIGURE 9.Model.A, IFN- triggers up-regulation of CIITA andMHC-IImolecules that leads to sustained antigen (Ag) presentation, T cells proliferation, and thus
increased IL-2 production. B,M. bovis BCG interacts with TLR2 that cross-talk with the NOTCH1 receptor. TLR2/NOTCH activation transduces the signal to the
nucleus through PKC-p38/JNK1/2-NFB culminating in expression of iNOS and consequently NO production. NO in turn, via KLF4, epigenetically suppresses
the expression of CIITA, the master co-activator of MHC-II molecules. This leads to inhibition of the macrophage responses to IFN- signaling, diminished
surface expression of MHC-II molecules, and reduced production of IL-2.
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late the KLF family of transcription factors is not documented.
In this perspective, the bifunctional nature of KLF4 has been
largely attributed to co-activators and co-repressors to which it
binds (44). Recent studies have determined the mechanisms by
which KLF4 can act as a suppressor or an activator; interaction
with co-activators such as p300 and cAMP-response element-
binding protein and repressors such as histone deacetylase-3
dictate its function (60–62). The current study underscores the
novel functions ofM. bovisBCG-inducedNO-responsive KLF4
to subdue CIITA expression through epigenetic modifications
as evidenced by in vivo and ex vivo experiments. The negative
regulation by KLF4 at the CIITA promoter is coordinated by
the histonemethyltransferase EZH2, a component of the PRC2
complex. Notably, literature evidences for the crucial role of epi-
genetic regulation of CIITA/MHC expression are available. For
example, inhibitionof chromatin remodeling factors likeBrahma-
related gene-1 (BRG-1) or histone acetylase recruitment to the
CIITApIV promoter by pathogenic mycobacteria or 19-kDa pro-
tein suppresses IFN--induced CIITA expression (14, 63, 64).
Mycobacteriumavium inhibits IFN- induced functions ofCIITA
by up-regulating the expression of mSin3A, and the histone
deacetylase-1 and -2-associated repressor, which facilitates
deacetylation at the CIITA promoter (48). The current investiga-
tion also ascribes the function of KLF4 as a positive regulator due
to its ability to induce miR-150 that targets CIITA. Epigenetic
modification rendered by non-coding RNA like miRNAs have
gained tremendous interest. Supporting the role for non-coding
RNA, the trophoblast non-coding RNA can suppress endogenous
aswell as transiently transfectedCIITApromoter activity (65, 66).
Together, these studies suggest the significanceofepigeneticmod-
ifications to control CIITA or MHC-II expression and activity.
Antigen presentation assays have further highlighted the impor-
tant role of KLF4 in this process.
Although various studies have implicated the role of kinases
and transcription factors in regulating IFN--induced CIITA
expression, our study presents a novel mechanism whereinM.
bovis BCG-mediated TLR2 signaling activates the NOTCH1-
PKC-p38-NF-B signaling axis to regulate iNOS expression and
NO production; NO-mediated down-regulation of MHC-II and
CIITA expression requires KLF4 (Fig. 9). Collectively our results
emphasize a novel finding that significantly contributes to the
ability ofmycobacteria to evade immune surveillance. It is clear
from our study that NO scavenger molecules and KLF4 inhib-
itors would present promising potential in therapeutics as well
as immunoprophylaxis of tuberculosis.
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SUPPLEMENTAL DATA 
 
SUPPLEMENTAL FIGURE 1. IFN-γ induces MHC-II and CIITA expression. A, Mouse peritoneal 
macrophages were treated with various concentrations of IFN- for 12 h and expression levels of MHC-II 
were assayed using immunoblotting. B, The kinetics of MHC-II expression in macrophages treated with 
100 ng IFN- at indicated time points. C, Analysis of CIITA expression in mouse peritoneal macrophages 
treated with indicated concentrations of IFN-. All blots shown are representative of 3 independent 
experiments and respective quantifications of immunoblots are shown. 
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SUPPLEMENTAL FIGURE 2. M. bovis BCG-induced iNOS/NO expression is dependent on 
NOTCH1 activation. A and B, Expression levels of iNOS was analysed using immunoblotting in mouse 
peritoneal macrophages infected with M. bovis BCG, (A) at various MOIs or (B) for various time points. 
C, The cell free supernatants obtained from the above mentioned experiment setup was assayed for NO 
production using Griess reagent. D and E, RAW 264.7 macrophages were transfected with pCMV or 
TLR2 DN constructs for 48 h followed by M. bovis BCG infection for 6 h and 12 h, (D) iNOS expression 
and (E) NO production was analysed by immunoblotting and using Greiss reagent respectively. F, Mouse 
peritoneal macrophages were infected with M. bovis BCG at indicated time points to assess the kinetics of 
NICD generation by immunobloting. G, Validation of the activity of Notch1 siRNA. H and I, 
Macrophages pretreated with GSI-I or transfected with Notch1 siRNA were infected with M. bovis BCG 
for 12 h and NO production was estimated using Griess reagent using culture supernatants. All blots 
shown are representative of 3 independent experiments. NO data represent mean ± SE, n = 3. Med, 
Medium; DN, dominant negative; NT, Non-targeting. * p<0.05, as compared to M. bovis BCG infected 
vector/NT siRNA transfected cells (one-way ANOVA). 
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SUPPLEMENTAL FIGURE 3. M. bovis BCG induced PKCδ, MAPK and NF-κB are the critical 
regulators of iNOS expression. A, Peritoneal macrophages were infected with M. bovis BCG for 
indicated time points and PKCδ activation was analysed by immunoblotting. B and C, RAW 264.7 
macrophages were transfected with pCMV or PKCδ DN for 48 h followed by infection with M. bovis 
BCG for 6 h and 12 h; (B) iNOS expression was assayed by immunoblotting and quantified and (C) NO 
production in culture supernatant was estimated by Greiss reagent respectively. D, The kinetics of p38 
and JNK1/2 MAPK activation with M. bovis BCG infection of mouse peritoneal macrophages is shown. 
E, Macrophages were treated with Chelerythrine and PKC Inhibitor 1 h prior to M. bovis BCG infection 
and activation of p38 MAPK was assessed by immunoblotting. F, Cytosolic to nuclear localization of p65 
NF-κB in peritoneal macrophages infected with M. bovis BCG at indicated time points as assessed by 
immunoblotting. All blots shown are representative of 3 independent experiments. NO data represent 
mean ± SE, n = 3. DMSO was used as vehicle control. Med, Medium; * p<0.005, as compared to M. 
bovis BCG infected pCMV transfected cells (one-way ANOVA). 
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SUPPLEMENTAL FIGURE 4. KLF4 inhibits IFN-γ induced MHC-II/CIITA expression. A and B, 
Murine RAW 264.7 macrophages were transiently transfected with pcDNA3.1 or KLF4 OE or KLF4 DN 
as indicated for 48 h followed by infection with M. bovis BCG for 12 h and IFN-γ treatment for the next 
48 h or 12 h, (A) representative immunofluorescence images (n = 3) of MHC-II surface expression and 
(B) immunoblotting for CIITA. All blots shown are representative of 3 independent experiments. Med, 
Medium; OE, Overexpression; DN, Dominant negative. Bar, 10 µm 
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SUPPLEMENTAL TABLE 1. Primers used for quantitative real time RT-PCR and ChIP analysis. 
Sr. No. Gene name Sequence 
Quantitative real time RT-PCR primers 
1 Gapdh forward 5’-gagccaaacgggtcatcatct-3’ 
 Gapdh reverse 5’-gaggggccatccacagtctt-3’ 
2 Mhc-II forward 5’-tgggcaccatcttcatcattc-3’ 
 Mhc-II reverse 5’-ggtcacccagcacaccactt-3’ 
3 CIITA forward 5’-gggactctggcaaatctcagg-3’ 
 CIITA reverse 5’-ctcatttacacgggaggtcagc-3’ 
   
Chromatin Immunoprecipitation primers 
1 28S rRNA forward 5’-ctgggtataggggcgaaagac-3’ 
 28S rRNA reverse 5’-ggccccaagacctctaatcat-3’ 
 For KLF4 binding at CIITA promoter 
2 KLF(-563) Forward 5’- gctgtcatgaggatgggact-3’ 
 KLF(-563) Reverse 5’- gcctttgtttccctgtgtgt-3’ 
3 KLF(-1251) Forward 5’- gccagatactgcttcctgatgtg-3’ 
 KLF(-1251) Reverse 5’- tcagggttgtggtggtaggca-3’ 
 For KLF4 binding at miR-150 promoter 
4 KLF(-430) Forward 5’-agacatttccaccgggagagg-3’ 
 KLF(-430) Reverse 5’-gcagagtctgtgagggaggg-3’ 
 
 
and Kithiganahalli Narayanaswamy Balaji
Devram Sampat Ghorpade, Sahana Holla, Akhauri Yash Sinha, Senthil Kumar Alagesan
 Bacillus Calmette-Guérin Infectionbovis
MycobacteriumRepress Major Histocompatibility Complex II Expression during 
Nitric Oxide and KLF4 Protein Epigenetically Modify Class II Transactivator to
doi: 10.1074/jbc.M113.472183 originally published online June 3, 2013
2013, 288:20592-20606.J. Biol. Chem. 
  
 10.1074/jbc.M113.472183Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
Supplemental material:
  
 http://www.jbc.org/content/suppl/2013/06/03/M113.472183.DC1.html
  
 http://www.jbc.org/content/288/28/20592.full.html#ref-list-1
This article cites 66 references, 37 of which can be accessed free at
 by guest on O
ctober 22, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
